Patents by Inventor Robert M. Ratcliffe
Robert M. Ratcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5955449Abstract: Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT).Type: GrantFiled: June 4, 1997Date of Patent: September 21, 1999Assignee: SYNSORB Biotech Inc.Inventors: Glen D. Armstrong, Robert M. Ratcliffe
-
Patent number: 5753631Abstract: The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention. The invention further includes immunoglobulins capable of selectively binding an oligosaccharide ligand that is recognized by a selectin receptor.Type: GrantFiled: May 31, 1995Date of Patent: May 19, 1998Assignee: Cytel CorporationInventors: James C. Paulson, Mary S. Perez, Federico C. A. Gaeta, Robert M. Ratcliffe
-
Patent number: 5679653Abstract: Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT).Type: GrantFiled: May 30, 1995Date of Patent: October 21, 1997Assignee: Synsorb Biotech Inc.Inventors: Glen D. Armstrong, Robert M. Ratcliffe
-
Patent number: 5620902Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the .alpha. anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.Type: GrantFiled: May 19, 1995Date of Patent: April 15, 1997Assignee: Alberta Research CouncilInventors: Robert M. Ratcliffe, Andre P. Venot, S. Zaheer Abbas
-
Patent number: 5620858Abstract: Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT).Type: GrantFiled: September 27, 1993Date of Patent: April 15, 1997Assignee: Synsorb Biotech Inc.Inventors: Glen D. Armstrong, Robert M. Ratcliffe
-
Patent number: 5576305Abstract: The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention.Type: GrantFiled: June 6, 1995Date of Patent: November 19, 1996Assignee: Cytel CorporationInventor: Robert M. Ratcliffe
-
Patent number: 5527901Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the .alpha. anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.Type: GrantFiled: December 22, 1993Date of Patent: June 18, 1996Assignee: Alberta Research CouncilInventors: Robert M. Ratcliffe, Andre P. Venot, S. Zaheer Abbas
-
Patent number: 5344870Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the .alpha. anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.Type: GrantFiled: March 17, 1992Date of Patent: September 6, 1994Assignee: Alberta Research CouncilInventors: Robert M. Ratcliffe, Andre P. Venot
-
Patent number: 5296594Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the a anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.Type: GrantFiled: June 28, 1990Date of Patent: March 22, 1994Assignee: Alberta Research CouncilInventors: Robert M. Ratcliffe, Andre P. Venot, S. Zaheer Abbas
-
Patent number: 5079353Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an a (2-3) or a (2-6) linkage is controlled to favor the a anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate a (2-3) and a (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.Type: GrantFiled: December 2, 1987Date of Patent: January 7, 1992Assignee: Chembiomed, Ltd.Inventors: Robert M. Ratcliffe, Andre P. Venot
-
Patent number: 4866041Abstract: Processes are provided for the syntheses of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(.beta.-D-galactopyranosyl)-.alpha.-D-galactopyran oside containing an .alpha.-O-glycosidically linked bridging arm O--(CH.sub.2).sub.n COR. The determinant is coupled to carrier molecules to form artificial T-antigens, and to insoluble supports to form T-immunoadsorbents. The artifical T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.Type: GrantFiled: September 1, 1988Date of Patent: September 12, 1989Assignee: Chembiomed, Ltd.Inventors: Raymond U. Lemieux, Robert M. Ratcliffe, Donald A. Baker
-
Patent number: 4855126Abstract: Processes are provided for the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(.beta.-D-galactopyranosyl)-.alpha.-D-galactopyran oside containing an .alpha.-O-glycosidically linked bridging arm O--(CH.sub.2).sub.n COR. The determinant is coupled to carrier molecules to form artificial T-antigens, and to insoluble supports to form T-immunoadsorbents. The artificial T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.Type: GrantFiled: August 17, 1987Date of Patent: August 8, 1989Assignee: Chembiomed Ltd.Inventors: Raymond U. Lemieuz, Robert M. Ratcliffe, Donald A. Baker
-
Patent number: 4794176Abstract: Processes are provided for the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(.beta.-D-galactopyranosyl)-.alpha.-D-galactopyran oside containing an .alpha.-O-glycosidically linked bridging arm O--(CH.sub.2).sub.n COR. The determinant is coupled to carrier molecules to form artifical T-antigens, and to insoluble supports to form T-immunoadsorbents. The artificial T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.Type: GrantFiled: October 15, 1986Date of Patent: December 27, 1988Assignee: ChembiomedInventors: Raymond U. Lemieux, Robert M. Ratcliffe, Donald A. Baker
-
Patent number: 4767845Abstract: Processes are provided for the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(.beta.-D-galactopyranosyl)-.alpha.-D-galactopyran oside containing an .alpha.-O-glycosidically linked bridging arm O--(CH.sub.2).sub.n COR. The determinant is coupled to carrier molecules to form artificial T-antigens, and to insoluble supports to form T-immunoadsorbents. The artifical T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.Type: GrantFiled: August 17, 1987Date of Patent: August 30, 1988Assignee: Chembiomed, Ltd.Inventors: Raymond U. Lemieux, Robert M. Ratcliffe, Donald A. Baker